Switch theme
Sign up to access all valuation multiples
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
1998
115
LTM Revenue $34.2M
LTM EBITDA -$11.5M
$325M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ClearPoint Neuro has a last 12-month revenue (LTM) of $34.2M and a last 12-month EBITDA of -$11.5M.
In the most recent fiscal year, ClearPoint Neuro achieved revenue of $31.4M and an EBITDA of -$17.8M.
ClearPoint Neuro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ClearPoint Neuro valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $34.2M | XXX | $31.4M | XXX | XXX | XXX |
| Gross Profit | $20.9M | XXX | $19.1M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$11.5M | XXX | -$17.8M | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -57% | XXX | XXX | XXX |
| EBIT | -$20.8M | XXX | -$19.7M | XXX | XXX | XXX |
| EBIT Margin | -61% | XXX | -63% | XXX | XXX | XXX |
| Net Profit | -$20.0M | XXX | -$18.9M | XXX | XXX | XXX |
| Net Margin | -58% | XXX | -60% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ClearPoint Neuro's stock price is $12.
ClearPoint Neuro has current market cap of $334M, and EV of $325M.
See ClearPoint Neuro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $325M | $334M | XXX | XXX | XXX | XXX | $-0.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ClearPoint Neuro has market cap of $334M and EV of $325M.
ClearPoint Neuro's trades at 10.3x EV/Revenue multiple, and -18.2x EV/EBITDA.
Equity research analysts estimate ClearPoint Neuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ClearPoint Neuro has a P/E ratio of -16.7x.
See valuation multiples for ClearPoint Neuro and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $334M | XXX | $334M | XXX | XXX | XXX |
| EV (current) | $325M | XXX | $325M | XXX | XXX | XXX |
| EV/Revenue | 9.5x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | -28.2x | XXX | -18.2x | XXX | XXX | XXX |
| EV/EBIT | -15.6x | XXX | -16.5x | XXX | XXX | XXX |
| EV/Gross Profit | 15.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -16.7x | XXX | -17.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -35.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialClearPoint Neuro's last 12 month revenue growth is 24%
ClearPoint Neuro's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
ClearPoint Neuro's rule of 40 is -63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ClearPoint Neuro's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ClearPoint Neuro and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | -34% | XXX | -57% | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -63% | XXX | -33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 124% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ClearPoint Neuro acquired XXX companies to date.
Last acquisition by ClearPoint Neuro was XXXXXXXX, XXXXX XXXXX XXXXXX . ClearPoint Neuro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ClearPoint Neuro founded? | ClearPoint Neuro was founded in 1998. |
| Where is ClearPoint Neuro headquartered? | ClearPoint Neuro is headquartered in United States of America. |
| How many employees does ClearPoint Neuro have? | As of today, ClearPoint Neuro has 115 employees. |
| Who is the CEO of ClearPoint Neuro? | ClearPoint Neuro's CEO is Mr. Joseph M. Burnett. |
| Is ClearPoint Neuro publicy listed? | Yes, ClearPoint Neuro is a public company listed on NAS. |
| What is the stock symbol of ClearPoint Neuro? | ClearPoint Neuro trades under CLPT ticker. |
| When did ClearPoint Neuro go public? | ClearPoint Neuro went public in 2012. |
| Who are competitors of ClearPoint Neuro? | Similar companies to ClearPoint Neuro include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ClearPoint Neuro? | ClearPoint Neuro's current market cap is $334M |
| What is the current revenue of ClearPoint Neuro? | ClearPoint Neuro's last 12 months revenue is $34.2M. |
| What is the current revenue growth of ClearPoint Neuro? | ClearPoint Neuro revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of ClearPoint Neuro? | Current revenue multiple of ClearPoint Neuro is 9.5x. |
| Is ClearPoint Neuro profitable? | Yes, ClearPoint Neuro is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ClearPoint Neuro? | ClearPoint Neuro's last 12 months EBITDA is -$11.5M. |
| What is ClearPoint Neuro's EBITDA margin? | ClearPoint Neuro's last 12 months EBITDA margin is -34%. |
| What is the current EV/EBITDA multiple of ClearPoint Neuro? | Current EBITDA multiple of ClearPoint Neuro is -28.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
